Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04343742|
Recruitment Status : Unknown
Verified May 2020 by Eduardo Insignares Carrione, Genesis Foundation.
Recruitment status was: Recruiting
First Posted : April 13, 2020
Last Update Posted : May 27, 2020
Abstract The objective of this study is to review, through prospective case research, the efficacy of oral chlorine dioxide in the treatment of patients with COVID infection 19. The research will be carried out between April and June 2020 with a quasi-experimental design in two health care centers on a sample of twenty (20) patients, through direct intervention, who will measure the changes in the manifest symptoms of infection and negativity. a COVID 19 after administration of the study preparation, to determine the effectiveness of chlorine dioxide in the treated group.
Based on the results that are found and on the evaluation of efficacy on the basis of clinical improvement on a scale of 1 to 5, and of the negativization of COVID 19, we can conclude whether the therapeutic efficacy in this investigation is considered good by verifying whether or not there is efficacy of treatment with chlorine dioxide in COVID 19.
With this research, it is hoped to stimulate the search for new therapeutic options in the treatment of COVID 19 and contribute to the development of NEW options in medications, considering the immense number of deaths and morbidity that currently exists in the present pandemic.
Key words: COVID 19, chlorine dioxide, treatment.
|Condition or disease||Intervention/treatment|
|COVID-19||Drug: chlorine dioxide 3000 ppm|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19|
|Actual Study Start Date :||April 1, 2020|
|Actual Primary Completion Date :||April 7, 2020|
|Estimated Study Completion Date :||June 1, 2020|
chlorine dioxide 3000 ppm. Bottle x 150 cc.
Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.
7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
Both the original dioxide bottle and the preparation for the day should be kept refrigerated.
Drug: chlorine dioxide 3000 ppm
Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.
: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
- negative testing of covid19 [ Time Frame: 7 DAYS ]amplification of coronavirus genes by RT-PCR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04343742
|Contact: EDUARDO INSIGNARES-CARRIONE, Research Direc.||+email@example.com|
|Contact: BLANCA BOLANO, firstname.lastname@example.org|
|Bogota, Cundinamarca, Colombia|
|Contact: YOHANY ANDRADE 3012629694 email@example.com|
|San Carlos Hospital||Recruiting|
|Bogota, Cundinamarca, Colombia|
|Contact: YOHANNY ANDRADE, INVESTIGATOR +573012629694 firstname.lastname@example.org|
|Study Chair:||yohanny andrade, researcher||Genesis Foundation|
|Study Chair:||oswaldo leyva, researcher||Genesis Foundation|